>>14474332 (/pb)
Trump took the vaccine, do you want to be vaccinated too??
get your head straight anon
True, he said that during the rally but we still don't know.
Then how can the other anon conclude Trump took Regeneron mAB"s and use that as his defense, even if Trump says he took it?
They use multiple mAB's to differing already mutate spike regions. This might help but you can still have escape mutations.
The phase 3 trial looked promising, but it can be deceiving.
You have to be cautious in promoting treatment to so many people via promotion when the prior study is done on a much smaller number, even if it shows promising results.
and if I am not mistaken, knowing what we know about the vaccines… it's odd that DeSantis wants the elderly to be vaccinated.
Just saying, homie
Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany
https://pubmed.ncbi.nlm.nih.gov/34278371/
They will house and be the ones contributing to escape mutations. Same deal.
Abstract
Background: Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient populations underrepresented in clinical trials, e.g. immunocompromised patients. Additionally, it is not well known to what extent SARS-CoV-2 treatment with monoclonal antibodies could trigger the selection of immune escape viral variants.
Methods: After identifying immunocompromised patients with viral rebound under treatment with bamlanivimab, we characterized the SARS-CoV-2-isolates by whole genome sequencing. Viral load measurements and sequence analysis were performed consecutively before and after bamlanivimab administration.
Findings: After initial decrease of viral load, viral clearance was not achieved in five of six immunocompromised patients treated with bamlanivimab. Instead, viral replication increased again over the course of the following one to two weeks. In these five patients, the E484K substitution - known to confer immune escape - was detected at the time of viral rebound but not before bamlanivimab treatment.
Interpretation: Treatment of SARS-CoV-2 with bamlanivimab in immunocompromised patients results in the rapid development of immune escape variants in a significant proportion of cases. Given that the E484K mutation can hamper natural immunity, the effectiveness of vaccination as well as antibody-based therapies, these findings may have important implications not only for individual treatment decisions but may also pose a risk to general prevention and treatment strategies.
We have suddenly started giving it to people who haven't tested positive and are not symptomatic but were near someone who 'has it' and is high risk… or not vaccinated….. the high risk categorization includes people who are not really high risk….. BMI >25 (taking into account that this virus can use cholesterol as a mechanism of entry).
I don't think this is appropriate to be promoting this at a mass scale under EUA and including extension for Post Ex prophylaxis…. I can be completely wrong, if I am I don't mind admitting it./// But this is a bad idea.